Borchmann P - Search Results

1

Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, Klimm B, Diehl V, Sasse S, Rothe A, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A. Eichenauer DA, et al. Among authors: borchmann p. Blood. 2014 Mar 13;123(11):1658-64. doi: 10.1182/blood-2013-07-512657. Epub 2014 Jan 29. Blood. 2014. PMID: 24478403 Free article.

2

[Chronic lymphatic leukemia. Progress in diagnosis and therapy].

Borchmann P, Diehl V, Engert A. Borchmann P, et al. Internist (Berl). 1996 Oct;37(10):1022-9. Internist (Berl). 1996. PMID: 9019446 Review. German. No abstract available.

3

A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.

Hübel K, Tesch H, Kröger B, Schnell R, Borchmann P, Diehl V, Engert A. Hübel K, et al. Among authors: borchmann p. Leukemia. 1997 Dec;11 Suppl 5:S47-51. Leukemia. 1997. PMID: 9436939 Clinical Trial.

4

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.

Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A. Schnell R, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Aug;30(5-6):525-37. doi: 10.3109/10428199809057565. Leuk Lymphoma. 1998. PMID: 9711915 Clinical Trial.

5

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, Wörmann B, Münch R, Diehl V, Engert A. Reiser M, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Oct;31(3-4):359-66. doi: 10.3109/10428199809059229. Leuk Lymphoma. 1998. PMID: 9869200 Clinical Trial.

6

New drugs in the treatment of Hodgkin's disease.

Borchmann P, Schnell R, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 1998;9 Suppl 5:S103-8. doi: 10.1093/annonc/9.suppl_5.s103. Ann Oncol. 1998. PMID: 9926247 Review.

7

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.

Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A. Schnell R, et al. Among authors: borchmann p. Leukemia. 2000 Jan;14(1):129-35. doi: 10.1038/sj.leu.2401626. Leukemia. 2000. PMID: 10637488 Clinical Trial.

8

Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.

Manzke O, Tesch H, Borchmann P, Wolf J, Lackner K, Gossmann A, Diehl V, Bohlen H. Manzke O, et al. Among authors: borchmann p. Int J Cancer. 2001 Feb 15;91(4):508-15. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1068>3.0.co;2-d. Int J Cancer. 2001. PMID: 11251974 Clinical Trial.

9

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

Borchmann P, Schnell R, Knippertz R, Staak JO, Camboni GM, Bernareggi A, Hübel K, Staib P, Schulz A, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 2001 May;12(5):661-7. doi: 10.1023/a:1011139016294. Ann Oncol. 2001. PMID: 11432625 Free article. Clinical Trial.

10

Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.

Pfitzner T, Reiser M, Barth S, Borchmann P, Schulz H, Schinköthe T, Oberhäuser F, Wessels J, Tur M, Diehl V, Engert A. Pfitzner T, et al. Among authors: borchmann p. Ann Hematol. 2002 May;81(5):258-66. doi: 10.1007/s00277-002-0449-4. Epub 2002 Apr 9. Ann Hematol. 2002. PMID: 12029535

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters